Hydroquinone 12% | Kojic Acid 6% | Ascorbic Acid 5%

Route: Topical. Apply a very thin layer to affected hyperpigmented areas only — avoid application to surrounding normal skin. Use once or twice daily as directed by the prescriber. Given the high concentrations, application to small affected areas (targeted lesional use) is essential. Daily broad-spectrum sunscreen (SPF ≥30) is mandatory. Limit application area and duration per prescriber direction to minimize systemic absorption and adverse effects.

Dosing is entirely prescriber-determined. Given the high active concentrations:

• Typically applied once to twice daily to targeted hyperpigmented lesions only.
• Treatment duration should be reassessed regularly; cycling with treatment breaks is recommended to reduce ochronosis risk.
• Prescribers should limit the treated surface area and monitor closely for adverse effects.

• Hydroquinone 12%: Competitively inhibits tyrosinase (blocking DOPA → melanin), disrupts melanosome structure and transfer, and at high concentrations exerts selective toxicity toward melanocytes via disruption of DNA/RNA synthesis and cytoskeletal structure.
• Kojic Acid 6%: Chelates copper at the tyrosinase active site (preventing its catalytic activity), inhibits the enzymatic oxidation of tyrosine → DOPA → melanin; additionally scavenges free radicals to reduce oxidative triggers for melanogenesis.
• Ascorbic Acid 5%: Inhibits tyrosinase by interacting with copper ions at the active site; acts as an antioxidant reducing dopaquinone back to DOPA (limiting melanin polymerization); neutralizes UV-generated ROS that stimulate melanocyte activity; also promotes collagen synthesis via hydroxylation reactions.

This high-potency combination is reserved for prescriber-directed management of severe, refractory melasma, persistent post-inflammatory hyperpigmentation, and other significant pigmentary disorders not adequately controlled by standard-concentration agents. All three ingredients target different steps in the melanin synthesis pathway, providing synergistic depigmenting effects. This formulation requires close dermatologic supervision due to the high HQ concentration (12%).

Monitoring: Assess at 4–8 weeks for irritant or allergic contact dermatitis, paradoxical hyperpigmentation, and ochronosis. Limit treatment area and duration. Require daily broad-spectrum photoprotection and re-evaluate treatment necessity at 3-month intervals.

Contraindications:

• Known hypersensitivity to hydroquinone, kojic acid, ascorbic acid, or formulation components.
• Pregnancy and lactation: significant skin surface areas treated with high-concentration HQ pose systemic absorption risk; avoid unless benefit clearly outweighs risk.
• Large body-surface-area application: systemic absorption risk with 12% HQ.

Warnings & Precautions:

• Ochronosis risk is significantly elevated at 12% HQ — limit treatment area, duration, and cycle treatment.
• Severe irritant contact dermatitis is possible at these concentrations; start with limited skin patch area.
• Kojic acid may cause contact sensitization in susceptible individuals.
• Ascorbic acid formulations may be unstable; oxidized (yellowed/brown) product should be discarded.

Drug Interactions:

• Avoid concurrent use of other potentially irritating topicals (retinoids, AHAs) without prescriber direction, as interaction may significantly increase skin irritation.

Common Side Effects: Erythema, burning, pruritus, contact dermatitis, skin dryness, photosensitivity. Risk of ochronosis increases with duration and concentration of HQ use.

Store at room temperature (15°C–25°C). Protect from light and air — both hydroquinone and ascorbic acid oxidize on light/air exposure (product turns brown/yellow; discard if discolored). Keep tightly sealed. Do not freeze. Use within the beyond-use date assigned by Genesis Compounding.

Why is this formulation so much stronger than standard hydroquinone products?

This 12% HQ combination is reserved for severe or refractory hyperpigmentation under close prescriber supervision. Standard prescription HQ is 4%; higher concentrations provide stronger depigmenting effects but carry proportionally higher risks of adverse effects, including ochronosis and skin irritation.

What does kojic acid add to this formula?

Kojic acid inhibits tyrosinase by chelating its copper ions, acting through a different mechanism than hydroquinone. Combined, they provide synergistic tyrosinase inhibition at multiple points and may produce more effective pigment reduction than either agent alone.

What does ascorbic acid (vitamin C) do in this cream?

Ascorbic acid inhibits tyrosinase through copper chelation, reduces oxidized melanin precursors back to non-pigmented forms, neutralizes free radicals that stimulate melanocytes, and supports collagen synthesis for overall skin quality improvement.

How do I prevent ochronosis with this high-strength preparation?

Apply only to targeted hyperpigmented lesions (not surrounding normal skin), cycle treatment with breaks under prescriber guidance, use the smallest effective amount, and follow the prescriber's recommended treatment duration limits. Report any new blue-grey or dark discoloration to your prescriber immediately.

Is this FDA-approved?

No. This is a patient-specific, prescriber-directed 503A compounded preparation from Genesis Compounding, not FDA-approved as a compounded drug.